

28 Nov 2021 | News

Quick Listen: Scrip's Five Must-Know Things

by [Ian Haydock](#)

In this week's podcast edition of Five Must-Know Things: the prospects and plans for J&J's pharma and oncology business; China looks more inward under new policies; an important US approval for Takeda; and Moderna's co-founder shares tips on innovation.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 12 November 2021, including: the prospects and plans for [Johnson & Johnson's](#) pharma and oncology business; China looks more inward under new policies; an important US approval for [Takeda Pharmaceutical Co. Ltd.](#); and [Moderna, Inc.](#)'s co-founder shares tips on innovation.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[No Way To Go But Grow: J&J Outlines Plans To Become A \\$60bn Pharma In 2025](#)" - Scrip, 18 Nov, 2021.)

(Also see "[Janssen's Lebowitz On J&J's Oncology Expansion Plans Outside Of Hematology](#)" - Scrip, 18 Nov, 2021.)

(Also see "[Pharma Will Need To Embrace More Inward-Looking China](#)" - Scrip, 24 Nov, 2021.)

(Also see "[Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients](#)" -

Scrip, 25 Nov, 2021.)

(Also see "[Moderna Co-Founder Robert Langer's Tips For Innovation](#)" - Scrip, 22 Nov, 2021.)

[Click here to explore this interactive content online](#) ✨